Benchmark Reiterates Buy on Belite Bio, Maintains $57 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bruce Jackson has reiterated a 'Buy' rating on Belite Bio (NASDAQ:BLTE) and maintained a price target of $57.

July 25, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Belite Bio's stock rating has been reiterated as 'Buy' by Benchmark analyst Bruce Jackson, with a maintained price target of $57.
The reiteration of a 'Buy' rating by a Benchmark analyst indicates a positive outlook for the company's stock. The maintained price target of $57 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100